A high degree of non-specific resistance to a lethal systemic infection was induced in mice by pretreatment with a small dose (>5 μUg/mouse) of the homologous lipopolysaccharide (LPS) or with heterologous rough-type LPS from K-12. The route of LPS administration, intraperitoneally or subcutaneously, did not influence the development of resistance, suggesting that a systemic cell activation was responsible for the effect. The enhanced elimination of bacteria was similar to that in mice recovering from a sublethal infection. In the LPS-treated mice, elimination of the challenge bacteria from the peritoneal cavity and the blood started 3–4 h after challenge whereas, in controls, the bacterial numbers continued to increase until the mice died. The detoxified LPS derivative, monophosphoryl lipid A (MPL), also increased the survival of mice infected with O18 :K1. However, the dose of MPL required for optimal infection resistance was 100-fold greater than that of native, K-12 LPS, corresponding to the 100-fold reduced toxicity of MPL for mice and rabbits in lethality and pyrogenicity assays.


Article metrics loading...

Loading full text...

Full text loading...


Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error